PHIO PHARMACEUTICALS CORP

PHIO represents shares of Phio Pharmaceuticals Corp., a clinical-stage biotechnology company. Its stock trades on the Nasdaq Capital Market under the ticker PHIO. As a small-cap biopharma, its value is closely tied to pipeline progress rather than commercial sales, since the company focuses on developing RNAi-based therapeutics. Investors can check the latest PHIO price and company data on this page.

PHIO operates in the biotechnology industry, specifically within the RNA interference (RNAi) therapeutics segment. The company develops immuno-oncology treatments designed to silence specific genes. This places it among clinical-stage biopharma firms, where research and development milestones, clinical trial results, and regulatory decisions often drive investor attention more than near-term revenue.

Recent performance for PHIO reflects the volatility typical of clinical-stage biotech stocks. Rather than relying on a static figure here, review the latest PHIO price chart on this page for current movement, including daily and year-to-date changes. News on trials, financing, or Nasdaq listing compliance can also influence short-term performance.

PHIO can be highly volatile because it is a small-cap, clinical-stage biotech with no approved products generating meaningful revenue. Price swings may follow clinical data, financing announcements, or broader market shifts. Daily percentage moves can be larger than large-cap averages. For current volatility measures such as beta or average trading volume, see the latest PHIO data on this page.

Key risks include clinical trial failure, regulatory delays, and the need for additional capital, which can dilute shareholders. As a small-cap company, PHIO may also face limited liquidity, Nasdaq listing requirements, and competition from larger biopharma firms. Its stock price can react sharply to any pipeline update, and the company may not achieve profitability from its RNAi programs.

PHIO does not pay dividends. As a clinical-stage biotechnology company, it typically reinvests any available capital into research, development, and clinical trials rather than returning cash to shareholders. Investors evaluating PHIO usually focus on pipeline progress and potential long-term capital appreciation, not income. For any future dividend announcements, check company press releases or the latest PHIO information on this page.